What does Sionna Therapeutics, Inc. do?
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial;…
What is Sionna Therapeutics, Inc.'s P/E and P/B ratio?
Sionna Therapeutics, Inc. has a P/E ratio of -1.8 and a P/B ratio of 0.65.
What is Sionna Therapeutics, Inc.'s debt-to-equity ratio?
Sionna Therapeutics, Inc. has a debt-to-equity ratio of 0.03.
How much does Sionna Therapeutics, Inc. owe compared with what it owns?
Sionna Therapeutics, Inc. owes $0.06 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Sionna Therapeutics, Inc.'s Positivity rank?
Sionna Therapeutics, Inc. is ranked #908 of 6,775 companies globally and #148 of 4,000 in United States on PositoAI, with a Positivity Score of 23,615.
Does Sionna Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Sionna Therapeutics, Inc..
Where can I read the latest news about Sionna Therapeutics, Inc.?
Recent headlines about Sionna Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Sionna Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Sionna Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.